1
|
Mallinckrodt BV, Thakur M, Weng A, Gilabert-Oriol R, Dürkop H, Brenner W, Lukas M, Beindorff N, Melzig MF, Fuchs H. Dianthin-EGF is an effective tumor targeted toxin in combination with saponins in a xenograft model for colon carcinoma. Future Oncol 2014; 10:2161-75. [DOI: 10.2217/fon.14.164] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022] Open
Abstract
ABSTRACT Aims: The intention of this work was to lift saponin supported tumor targeted therapies onto the next level by using targeted toxins in nude mice xenotransplant models. Materials & methods: Combined application of dianthin coupled to EGF and saponin SO-1861 was tested in a xenograft model of colon carcinoma. In vitro cytotoxicity was tested in real-time in NIH3T3 cells (no human EGF receptor expression), HER14 and human colon carcinoma HCT116 (both EGF receptor overexpressing) cells. A xenograft model was established using HCT116 cells and tumor-bearing animals were treated with SO-1861 (30 µg/treatment) and dianthin coupled to EGF (0.35 µg/treatment). Tumor progression was monitored, using 18F-2-fluor-2-desoxy-d-glucose, by small animal PET and by x-ray computed tomography. Results: In vitro results demonstrated a high-receptor specificity and the in vivo experiment showed a progressive reduction of the tumor volume and glycolytic activity in the treated group (>95% reduction; p < 0.05). Conclusion: This therapy has great advantage because of high specificity, low side effects and great effectiveness for future development in the treatment of colon cancer.
Collapse
Affiliation(s)
- Benedicta von Mallinckrodt
- Institute for Laboratory Medicine, Clinical Chemistry & Pathobiochemistry, Charité – Universitätsmedizin Berlin, Campus Virchow-Klinikum, Augustenburger Platz 1, 13353 Berlin, Germany
| | - Mayank Thakur
- Institute for Laboratory Medicine, Clinical Chemistry & Pathobiochemistry, Charité – Universitätsmedizin Berlin, Campus Virchow-Klinikum, Augustenburger Platz 1, 13353 Berlin, Germany
| | - Alexander Weng
- Institute for Laboratory Medicine, Clinical Chemistry & Pathobiochemistry, Charité – Universitätsmedizin Berlin, Campus Virchow-Klinikum, Augustenburger Platz 1, 13353 Berlin, Germany
| | - Roger Gilabert-Oriol
- Institute for Laboratory Medicine, Clinical Chemistry & Pathobiochemistry, Charité – Universitätsmedizin Berlin, Campus Virchow-Klinikum, Augustenburger Platz 1, 13353 Berlin, Germany
| | - Horst Dürkop
- Pathodiagnostik Berlin, Referenzzentrum für Lymphom-und Hämatopathologie, Komturstraße 58, Berlin, Germany
| | - Winfried Brenner
- Department of Nuclear Medicine Charité – Universitätsmedizin Berlin, Campus Virchow-Klinikum, Augustenburger Platz 1, 13353 Berlin
| | - Mathias Lukas
- Department of Nuclear Medicine Charité – Universitätsmedizin Berlin, Campus Virchow-Klinikum, Augustenburger Platz 1, 13353 Berlin
- Department of Nuclear Medicine, Technical University Munich, Klinikum rechts der Isar, Ismaninger Straße 22, 81675 Munich, Germany
| | - Nicola Beindorff
- Department of Nuclear Medicine Charité – Universitätsmedizin Berlin, Campus Virchow-Klinikum, Augustenburger Platz 1, 13353 Berlin
| | - Matthias F Melzig
- Institute of Pharmacy, Free University Berlin, Königin-Luise-Straße 2+4, 14195 Berlin, Germany
| | - Hendrik Fuchs
- Institute for Laboratory Medicine, Clinical Chemistry & Pathobiochemistry, Charité – Universitätsmedizin Berlin, Campus Virchow-Klinikum, Augustenburger Platz 1, 13353 Berlin, Germany
| |
Collapse
|
2
|
Barnea I, Ben-Yosef R, Karaush V, Benhar I, Vexler A. Targeting EGFR-positive cancer cells with cetuximab-ZZ-PE38: Results of in vitro and in vivo studies. Head Neck 2012; 35:1171-7. [DOI: 10.1002/hed.23093] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 05/25/2012] [Indexed: 11/09/2022] Open
|